@article{946be07398c64dc99112917e221bf666,
title = "Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP)",
keywords = "PROGRAMMED DEATH LIGAND-1, CLINICAL BENEFIT, RADIOTHERAPY, EXPRESSION, MAGNITUDE, PD-L1",
author = "S. Peters and U. Dafni and M. Boyer and {De Ruysscher}, D. and C. Faivre-Finn and E. Felip and P. Garrido and N. Girard and M. Guckenberger and J. Haanen and {Le Pechoux}, C. and F. Mornex and M. Ozsahin and L. Paz-Ares and D. Planchard and D. Raben and S. Ramalingam and M. Reck and E. Smit and R. Stahel and A. Stenzinger and C. Swanton and S. Vallone and Garassino, {M. C.}",
year = "2019",
month = feb,
doi = "10.1093/annonc/mdy553",
language = "English",
volume = "30",
pages = "161--165",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "2",
}